MX2017015909A - Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. - Google Patents
Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.Info
- Publication number
- MX2017015909A MX2017015909A MX2017015909A MX2017015909A MX2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A
- Authority
- MX
- Mexico
- Prior art keywords
- cognitive function
- enhancing cognitive
- h3k9me3
- modulation
- h3k9me3 modulation
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 abstract 1
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Amplifiers (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Networks Using Active Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172690P | 2015-06-08 | 2015-06-08 | |
| PCT/US2016/035764 WO2016200690A1 (en) | 2015-06-08 | 2016-06-03 | USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015909A true MX2017015909A (es) | 2018-05-07 |
Family
ID=57504356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015909A MX2017015909A (es) | 2015-06-08 | 2016-06-03 | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10272093B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3733188B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6851081B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102776570B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107849061B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016276172B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2988568A1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2944446T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256055B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017015909A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016200690A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2988568A1 (en) * | 2015-06-08 | 2016-12-15 | The Regents Of The University Of California | Use of h3k9me3 modulation for enhancing cognitive function |
| US20200147099A1 (en) * | 2017-06-20 | 2020-05-14 | Institut Curie | Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy |
| CN108434454B (zh) * | 2018-03-16 | 2019-10-11 | 大连医科大学 | Adar1在缓解认知功能障碍方面的应用 |
| JP7716987B2 (ja) * | 2019-05-02 | 2025-08-01 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Tert活性化療法を伴う方法および組成物 |
| US20240009203A1 (en) * | 2020-08-03 | 2024-01-11 | Cedars-Sinai Medical Center | Compositions and methods for treating alzheimer's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534255B1 (en) * | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
| US20060019227A1 (en) * | 2004-07-22 | 2006-01-26 | Hardwicke Susan B | Methods for cognitive treatment |
| US8221804B2 (en) * | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| CA2649576A1 (en) * | 2006-06-09 | 2007-12-21 | Wyeth | Method for enhancing cognitive function |
| JP2009084271A (ja) * | 2007-09-07 | 2009-04-23 | Toyama Univ | 脳由来神経栄養因子の発現誘導剤および発現誘導方法 |
| CN102271763A (zh) * | 2008-12-03 | 2011-12-07 | 麻省理工学院 | 抑制hdac2以促进记忆 |
| DK2542084T3 (en) * | 2010-03-04 | 2018-03-26 | Merck Sharp & Dohme | CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND THEIR USE IN TREATMENT OF PSYCHOTIC DISORDERS |
| KR101235256B1 (ko) * | 2010-09-13 | 2013-02-21 | 서울대학교산학협력단 | miRNA를 타겟으로 한 신경퇴행성 질환 치료 |
| CA2900335C (en) * | 2012-10-22 | 2021-10-26 | City Of Hope | Synthetic analogs of epipolythiodioxopiperazines and uses thereof |
| US20160058754A1 (en) * | 2013-04-17 | 2016-03-03 | H. Lundbeck A/S | Nalmefene for Treatment of Patients with Anxiety Disorder |
| CA2930874A1 (en) * | 2013-11-26 | 2015-06-04 | University Of North Texas Health Science Center At Fort Worth | Personalized medicine approach for treating cognitive loss |
| CA2988568A1 (en) * | 2015-06-08 | 2016-12-15 | The Regents Of The University Of California | Use of h3k9me3 modulation for enhancing cognitive function |
-
2016
- 2016-06-03 CA CA2988568A patent/CA2988568A1/en active Pending
- 2016-06-03 ES ES20172824T patent/ES2944446T3/es active Active
- 2016-06-03 MX MX2017015909A patent/MX2017015909A/es unknown
- 2016-06-03 AU AU2016276172A patent/AU2016276172B2/en active Active
- 2016-06-03 KR KR1020187000444A patent/KR102776570B1/ko active Active
- 2016-06-03 EP EP20172824.3A patent/EP3733188B1/en active Active
- 2016-06-03 JP JP2017563134A patent/JP6851081B2/ja active Active
- 2016-06-03 ES ES16808065T patent/ES2807878T3/es active Active
- 2016-06-03 WO PCT/US2016/035764 patent/WO2016200690A1/en not_active Ceased
- 2016-06-03 CN CN201680040210.0A patent/CN107849061B/zh active Active
- 2016-06-03 US US15/580,419 patent/US10272093B2/en active Active
- 2016-06-03 EP EP16808065.3A patent/EP3303347B1/en active Active
-
2017
- 2017-12-03 IL IL256055A patent/IL256055B/en unknown
-
2019
- 2019-03-15 US US16/354,996 patent/US10849910B2/en active Active
- 2019-10-11 AU AU2019246902A patent/AU2019246902B2/en active Active
-
2020
- 2020-10-16 US US17/072,539 patent/US11311551B2/en active Active
-
2022
- 2022-03-17 US US17/697,893 patent/US20230057592A1/en not_active Abandoned
-
2024
- 2024-02-14 US US18/441,939 patent/US20240374608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019246902B2 (en) | 2021-08-19 |
| CN107849061A (zh) | 2018-03-27 |
| KR20180014432A (ko) | 2018-02-08 |
| CN107849061B (zh) | 2021-05-14 |
| EP3733188B1 (en) | 2023-01-25 |
| WO2016200690A1 (en) | 2016-12-15 |
| US10849910B2 (en) | 2020-12-01 |
| JP6851081B2 (ja) | 2021-03-31 |
| ES2807878T3 (es) | 2021-02-24 |
| AU2019246902A1 (en) | 2019-10-31 |
| US20240374608A1 (en) | 2024-11-14 |
| US20230057592A1 (en) | 2023-02-23 |
| EP3733188A1 (en) | 2020-11-04 |
| IL256055A (en) | 2018-01-31 |
| US20180228808A1 (en) | 2018-08-16 |
| EP3303347B1 (en) | 2020-05-06 |
| AU2016276172B2 (en) | 2019-07-11 |
| US10272093B2 (en) | 2019-04-30 |
| ES2944446T3 (es) | 2023-06-21 |
| US11311551B2 (en) | 2022-04-26 |
| EP3303347A4 (en) | 2019-03-06 |
| EP3303347A1 (en) | 2018-04-11 |
| AU2016276172A1 (en) | 2018-01-04 |
| KR102776570B1 (ko) | 2025-03-04 |
| CA2988568A1 (en) | 2016-12-15 |
| US20210106590A1 (en) | 2021-04-15 |
| US20190209577A1 (en) | 2019-07-11 |
| JP2018516940A (ja) | 2018-06-28 |
| IL256055B (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550857A1 (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| IL292302B1 (en) | Use of glutamate modulating factors in cancer immunotherapy | |
| MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
| PT4303583T (pt) | Inibidores de csf1r para utilização no tratamento de tumores tenossinoviais de células gigantes | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| MX368833B (es) | Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor. | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| MX2015002755A (es) | 1,3-dioxanomorfidas y 1,3-dioxanocodidas. | |
| MX2017015909A (es) | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. | |
| MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
| IL242853B (en) | Preparations containing dianhydrogalactitol or analogues or derivatives of dianhydrogalactitol for the treatment of sarcoid glioma or an advanced secondary brain tumor | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| GEP20186864B (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
| WO2015100092A3 (en) | 7-beta analogs of orvinols | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| MX383323B (es) | Grelina para uso en el tratamiento de lesión del cerebro traumática leve. | |
| IL259153A (en) | Use of proteasome inhibitors to treat ocular disorders | |
| NZ713129A (en) | Oxprenolol compositions for treating cancer | |
| SG11202103588WA (en) | Use of reboxetine to treat narcolepsy | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| IL291424A (en) | Use of dkk-1 inhibitors for treating cancer |